Aytu Biopharma (AYTU) Finished Goods (2019 - 2026)

Aytu Biopharma (AYTU) has 8 years of Finished Goods data on file, last reported at $4.0 million in Q1 2026.

• Finished Goods for Q1 2026 came in at $4.0 million, down 52.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (down 52.24% YoY), and the FY2025 annual result was $8.9 million, up 45.33% from the prior year.
• Finished Goods fell to $4.0 million in Q1 2026 per AYTU's latest filing, from $5.6 million in the prior quarter.
• Over five years, Finished Goods peaked at $9.9 million in Q1 2022 and troughed at $4.0 million in Q1 2026.
• A 5-year average of $7.6 million and a median of $7.7 million in 2023 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2025 and 2026: Finished Goods surged 45.33% in 2025, then sank 52.24% in 2026.
• A 5-year view of Finished Goods shows it stood at $8.4 million in 2022, then rose by 3.73% to $8.7 million in 2023, then retreated by 13.66% to $7.5 million in 2024, then declined by 24.81% to $5.6 million in 2025, then decreased by 28.22% to $4.0 million in 2026.
• Business Quant data shows AYTU's Finished Goods at $4.0 million in Q1 2026, $5.6 million in Q4 2025, and $7.9 million in Q3 2025.